A META-ANALYSIS OF PIPERACILLIN/TAZOBACTAM VERSUS CEFEPIME TREATMENT IN CANCER PATIENTS WITH FEBRILE NEUTROPENIA

被引:0
|
作者
Zhang Weidong [1 ]
Xiao Chun [2 ]
Zhou Sixin [3 ]
Wang Rui [1 ]
Wang Li [1 ]
Jia Liping [1 ]
Ma Jinqiu [1 ]
Wang Na [1 ]
机构
[1] First Hosp Qinhuangdao, Qinhuangdao 066000, Peoples R China
[2] PLA Rocket Force, Gen Hosp, Dept Gen Surg, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing 100853, Peoples R China
来源
BIOSCIENCE JOURNAL | 2016年 / 32卷 / 06期
关键词
Meta-analysis; Piperacillin/Tazobactam; Cefepime; Febrile neutropenia; Cancer; STEM-CELL TRANSPLANTATION; EMPIRICAL-TREATMENT; OPEN-LABEL; MONOTHERAPY; TAZOBACTAM; MULTICENTER; MANAGEMENT; THERAPY; FEVER; CHEMOTHERAPY;
D O I
暂无
中图分类号
S [农业科学];
学科分类号
09 ;
摘要
Febrile neutropenia (FN) causes a major threat to cancer patients after chemotherapy. Broad-spectrum antibiotic treatment is a well-established practice for febrile neutropenia. Piperacillin/Tazobactam (P/T) is the frequently used antibiotic in most of FN cases, whereas the use of cefepime remains unclear regarding its potential risk. However, little systematic analysis has been conducted about comparison between these two drugs. Thus, we undertook this meta-analysis to compare these two monotherapies for febrile neutropenia. Through searching Pubmed, Google scholar, Medline databases, EMBASE, OvidSP, ScienceDirect, Web of science, and China Journal Net (CJN) databases, we used the keywords "(Piperacillin/Tazobactam AND cefepime) AND (febrile neutropenia) AND (cancer or tumor)". Only studies with randomized controlled trials were included in the meta-analysis. We screened out a total number of seven clinical trials. This meta-analysis supported that P/T treatment was superior to cefepime treatment based on the average OR comparison, without statistical significance (OR = 1.27, 95% confidence interval = 0.98 to 1.64, p = 0.07). We further divided the seven studies into two subgroups based on age and treatment time. The young group (age <= 19) showed no significant difference (OR = 1.10, p = 0.65). While the old group (age > 19) showed that P/T treatment was better than cefepime with statistical difference (OR = 1.44, p = 0.05). The short-term group (time <= 3 ds) showed P/T treatment was better than cefepime with statistical difference (OR = 1.40, p = 0.05). While in the long-term group (time > 5 ds), there was no significant difference between P/T and cefepime therapy (OR = 1.06, p = 0.79) Asymmetry in Funnel plots indicated no publication bias (CHI2 = 1.47, I-2 = 0%, and p-value = 0.96) in this meta-analysis. It would be a good clinical trial to use P/T treatment to cure FN in cancer patients compared with cefepime treatment, especially in adult patients or patients with a short-term treatment period. This meta-analysis is practically important during antibiotic treatment in FN management.
引用
收藏
页码:1669 / 1678
页数:10
相关论文
共 50 条
  • [1] Comparative Study of Piperacillin/Tazobactam and Cefepime in Cancer Patients with Febrile Neutropenia
    Wi, Y. M.
    Chung, D. R.
    Song, J. H.
    Peck, K. R.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 : E401 - E401
  • [2] Piperacillin-tazobactam versus cefepime monotherapy for pediatric febrile neutropenia.
    Kebudi, R
    Ayan, I
    Görgün, Ö
    Gürler, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 812S - 812S
  • [3] Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: A randomized comparison
    Corapcioglu, F
    Sarper, N
    Zengin, E
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2006, 23 (03) : 177 - 186
  • [4] Piperacillin/Tazobactam Versus Cefozopran for the Empirical Treatment of Pediatric Cancer Patients With Febrile Neutropenia
    Ichikawa, Mizuho
    Suzuki, Daisuke
    Ohshima, Junjiro
    Cho, Yuko
    Kaneda, Makoto
    Iguchi, Akihiro
    Ariga, Tadashi
    PEDIATRIC BLOOD & CANCER, 2011, 57 (07) : 1159 - 1162
  • [5] Piperacillin/Tazobactam Versus Cefepime for the Empirical Treatment of Pediatric Cancer Patients With Neutropenia and Fever: A Randomized and Open-Label Study
    Uygun, Vedat
    Karasu, Gulsun Tezcan
    Ogunc, Dilara
    Yesilipek, Akif
    Hazar, Volkan
    PEDIATRIC BLOOD & CANCER, 2009, 53 (04) : 610 - 614
  • [6] Use of cefepime, meropenem, or piperacillin/tazobactam as initial treatment for febrile neutropenia in patients with hematological malignancy — a real-life experience
    Najmul Karim
    Alamgir Kabir
    Manirul Islam
    Akhil Ranjan Biswas
    Mohammed Wasim
    Mahbubul Alam
    Nobendu Chowdhury
    Mohammed Nadimul Islam
    Tamanna Tabassum
    Mohammad Jahid Hasan
    The Egyptian Journal of Internal Medicine, 2022, 34
  • [7] Use of cefepime, meropenem, or piperacillin/tazobactam as initial treatment for febrile neutropenia in patients with hematological malignancy - a real-life experience
    Karim, Najmul
    Kabir, Alamgir
    Islam, Manirul
    Biswas, Akhil Ranjan
    Wasim, Mohammed
    Alam, Mahbubul
    Chowdhury, Nobendu
    Islam, Mohammed Nadimul
    Tabassum, Tamanna
    Hasan, Mohammad Jahid
    EGYPTIAN JOURNAL OF INTERNAL MEDICINE, 2022, 34 (01):
  • [8] Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy
    José C Álvarez
    Sonia I Cuervo
    Javier R Garzón
    Julio C Gómez
    Jorge Augusto Díaz
    Edelberto Silva
    Ricardo Sánchez
    Jorge A Cortés
    BMC Pharmacology and Toxicology, 14
  • [9] Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy
    Alvarez, Jose C.
    Cuervo, Sonia I.
    Garzon, Javier R.
    Gomez, Julio C.
    Diaz, Jorge Augusto
    Silva, Edelberto
    Sanchez, Ricardo
    Cortes, Jorge A.
    BMC PHARMACOLOGY & TOXICOLOGY, 2013, 14 : 59
  • [10] Meropenem Versus Piperacillin-Tazobactam as Empiric Therapy for Febrile Neutropenia in Pediatric Oncology Patients
    Sezgin, Gulay
    Acipayam, Can
    Ozkan, Ayse
    Bayram, Ibrahim
    Tanyeli, Atila
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (11) : 4549 - 4553